Published in Vaccine Weekly, November 27th, 2002
"In mice, depletion of regulatory T cells by antibody therapy leads to more efficient tumor rejection," said Udaya K. Liyanage and colleagues at the Alvin J. Siteman Cancer Center in St. Louis. "Regulatory T cell-medicated suppression of antitumor immune responses may partly explain the poor clinical response to vaccine-based immunotherapy for human cancer."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.